Consensus Arcus Biosciences, Inc.

Stocks

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - NYSE 21:00:03 31/08/2026 BST			5-day change	1st Jan Change
29.28 ^USD	+0.24%		-2.79%	+22.87%

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT

Evolution of the Average Target: Arcus Biosciences, Inc.

Evolution of the Target Price: Arcus Biosciences, Inc.

Changes in Analyst Recommendations: Arcus Biosciences, Inc.

5a8a85e1520d1ac3b6716a8c2e.OfrEbDgoT76zx9f5_gK4jVlBRl9uCUWxCn0WbmQ8yb4.e5SuM3peYtaEj4iPp1jC1zc7cRANUXeAMipMFFdXpNNuw4kddU4d8PCf4w~5635ca61d07fbf40b24c5991cf70dcef

Analysts' recommendations: Arcus Biosciences, Inc.

08-10	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
08-10	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT
08-06	Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating	MT
08-03	BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25	MT
04-21	Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says	MT
04-02	Wedbush Raises Price Target on Arcus Biosciences to $41 From $37, Keeps Outperform Rating, Adds Stock to Best Ideas List	MT
02-12	Wells Fargo Downgrades Arcus Biosciences to Equal Weight From Overweight, Adjusts PT to $23 From $30	MT
01-08	Morgan Stanley Downgrades Arcus Biosciences to Equal Weight From Overweight, Cuts Price Target to $20 From $23	MT
12-12	Wedbush Adjusts Arcus Biosciences Price Target to $37 From $35, Maintains Outperform Rating	MT
12-12	Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating	MT
11-03	Mizuho Raises Price Target on Arcus Biosciences to $47 From $45, Keeps Outperform Rating	MT
29/10/25	Wedbush Raises Price Target on Arcus Biosciences to $35 From $33, Keeps Outperform Rating	MT
14/10/25	Arcus Biosciences, Inc. Announces First Overall Survival Results from Arm A1 of the Phase 2 EDGE-Gastric Study	CI
07/10/25	Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating	MT
18/08/25	Mizuho Raises Price Target on Arcus Biosciences to $45 From $42, Keeps Outperform Rating	MT
07/08/25	Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating	MT
06/08/25	Arcus Biosciences Q2 revenue beats analyst expectations	RE
09/05/25	Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating	MT
26/02/25	HC Wainwright Upgrades Arcus Biosciences to Buy From Neutral, Adjusts Price Target to $24 From $18	MT
18/02/25	Wedbush Cuts Arcus Biosciences' Price Target to $33 From $36, Keeps Outperform Rating	MT
21/10/24	HC Wainwright Initiates Coverage on Arcus Biosciences With Neutral Rating, $20 Price Target	MT
08/10/24	Wells Fargo Initiates Arcus Biosciences at Overweight With $29 Price Target	MT
24/06/24	Truist Lowers Price Target on Arcus Biosciences to $44 From $50, Maintains Buy Rating	MT
03/06/24	Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating	MT
30/01/24	Mizuho Adjusts Arcus Biosciences' Price Target to $42 From $51, Keeps Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARCUS BIOSCIENCES, INC.					+30.92%
	LONZA GROUP AG					+18.13%
	REVOLUTION MEDICINES, INC.					+21.02%
	IQVIA HOLDINGS INC.					+5.35%
	BEONE MEDICINES AG					+20.18%
	CELLTRION, INC.					+40.83%
	MEDPACE HOLDINGS, INC.					-2.05%
	ASCENDIS PHARMA A/S					+19.48%
	EUROFINS SCIENTIFIC SE					-0.02%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					-2.51%
	Average					+15.13%
	Weighted average by Cap.					+16.69%